UBRELVY: Uses, Forms and Safety Reference

UBRELVY contains ubrogepant for treating migraine attacks in adults. Its acute-treatment role is separate from prevention, and interactions can affect whether and when another dose is allowed.

The approved uses and formulations described here follow US prescribing information. They may differ in other countries.

Medicine detail Details
Active ingredient(s) ubrogepant
Medicine class Calcitonin gene-related peptide (CGRP) receptor antagonist
Forms and strengths Oral tablets: 50 and 100 mg

An attack medicine rather than prevention

UBRELVY is US-labeled for acute migraine with or without aura in adults. It is not indicated for preventive migraine treatment. The medicine blocks CGRP receptors; sharing that pathway with other products does not mean those products have the same role or instructions.

Source: [1]

Two tablet strengths with qualified directions

The tablets contain 50 or 100 mg of ubrogepant and can be taken with or without food. The label permits a second dose in some circumstances, but interactions and organ impairment change the instructions. Follow the prescription and check before repeating; tablet availability does not determine personal suitability.

Source: [1]

Check interacting medicines before a repeat dose

Strong CYP3A4 inhibitors are contraindicated. Other inhibitors or inducers and BCRP or P-gp inhibitors can require dose changes or avoidance. Severe kidney or liver impairment affects prescribing, and end-stage renal disease is a reason to avoid use. A pharmacist should review the exact combination, including nonprescription products.

Source: [1]

Allergic and vascular reactions

Serious allergic reactions can develop within minutes, hours or days. Breathing difficulty or swelling needs emergency assessment. New or worsening high blood pressure and Raynaud's phenomenon are also labeled warnings. New painful, cold or discolored fingers or toes should be reported promptly rather than assumed to be part of migraine.

Source: [1]

Frequent attacks need a treatment review

Nausea and sleepiness are reported adverse effects. The label states that safety of treating more than eight migraines in 30 days is not established. More frequent need is a reason to discuss the migraine plan with the clinician, including the distinction between acute treatment and prevention, without independently combining CGRP medicines.

The NURTEC ODT and UBRELVY comparison brings the two product identities and selected label facts together for further reading.

Source: [1]

Questions and answers

Is UBRELVY approved as a daily preventive medicine?

No. The cited US indication is acute treatment of adult migraine, not prevention.

Can every prescription allow the same repeat dose?

No. Interactions and kidney or liver impairment can change repeat-dose instructions.

Why report new finger or toe color changes?

The label warns about Raynaud's phenomenon, a circulation problem that can develop or worsen during treatment.

Related reading

Sources

  1. UBRELVY: official US prescribing information

Sources checked 27 October 2026. This information does not replace advice from your healthcare professional. For complete warnings and instructions, read the product information and consult the prescribing team.

Reviewed by: Mattias Hagman, PhD

About the reviewer:
Dr Mattias Hagman (PhD, University of Sydney) has an academic background and experience working with healthcare-related content and regulated industries. He has lecturing experience at international universities, including Stockholm University and the University of Malta.

Last reviewed: October 2026